Table of Contents

State/Territory Name: Alabama

State Plan Amendment (SPA) #: 13-011

This file contains the following documents in the order listed:

- 1) Regional Office Follow-up Approval Letter
- 2) Pharmacy Approval Letter
- 3) CMS 179 Form
- 4) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
Atlanta Regional Office
61 Forsyth Street, Suite 4T20
Atlanta, GA 30303



DIVISION OF MEDICAID & CHILDREN'S HEALTH OPERATIONS

August 5, 2013

Stephanie McGee Azar Acting Commissioner Alabama Medicaid Agency 501 Dexter Avenue Post Office Box 5624 Montgomery, Alabama 36103-5624

RE: Title XIX State Plan Amendment (SPA), Transmittal # AL 13-011

Dear Ms. Azar:

This is to affirm approval of the above referenced State Plan Amendment which was submitted to the Regional Office on May 3, 2013. The State's requested effective date of July 1, 2013 has been accepted.

Enclosed for your records are:

- 1. a copy of the approval letter dated July 25, 2013 that was submitted to the State by Larry Reed, Director, Division of Pharmacy;
- 2. the original signed 179; and
- 3. the approved plan page.

If you have any additional questions regarding this amendment, please contact Melanie Johnson, State Coordinator for Alabama, at 404-562-0151.

Sincerely,

//s//

Jackie Glaze Associate Regional Administrator Division of Medicaid and Children's Health Operations

Enclosures

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Disabled & Elderly Health Programs Group

July 25, 2013

Stephanie McGee Azar Acting Commissioner Alabama Medicaid Agency 501 Dexter Avenue P.O. Box 5624 Montgomery, AL 36103-5624

Dear Ms. Azar:

We have reviewed the Alabama State Plan Amendment (SPA) 13-011 received in the Atlanta Regional Office on May 3, 2013. The State of Alabama proposes to amend its supplemental rebate agreement to facilitate obtaining drug rebates in addition to the federal rebate provided for under Title XIX. Based on the information provided, we are pleased to inform you that SPA 13-011 is approved with an effective date of July 1, 2013.

A copy of the CMS-179 form as well as the pages approved for incorporation into the state plan will be forwarded by the Atlanta Regional Office. If you have any questions regarding this amendment, please contact Madlyn Kruh at (410) 786-3239.

Sincerely,

/s/

Larry Reed Director Division of Pharmacy

cc: Jackie Glaze, ARA, Atlanta Regional Office Melanie Johnson, Atlanta Regional Office

| DEPARTMENT OF HEALTH AND HUMAN SERVICES HEALTH CARE FINANCING ADMINISTRATION | | FORM APPROVED OMB NO. 0938-0193 |
|--|--|---------------------------------|
| TRANSMITTAL AND NOTICE OF APPROVAL OF | 1. TRANSMITTAL NUMBER: | 2. STATE |
| STATE PLAN MATERIAL | AL-13-011 | Alabama |
| SINIE I LAN MATERIAL | | |
| FOR: HEALTH CARE FINANCING ADMINISTRATION | 3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID) | |
| TO: REGIONAL ADMINISTRATOR | 4. PROPOSED EFFECTIVE DATE | |
| HEALTH CARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES | July 1, 2013 | |
| 5. TYPE OF PLAN MATERIAL (Check One): | | |
| | • • • | _ |
| | CONSIDERED AS NEW PLAN | |
| COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME | | h amendment) |
| 6. FEDERAL STATUTE/REGULATION CITATION: | 7. FEDERAL BUDGET IMPACT: | |
| 42 CFR Section 447.15, 447.331 & Section 401 | a. FFY 2013 0 | |
| | b. FFY 2014 0 | |
| 8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT: | 9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable): | |
| Attachment 3.1-A page 5.12b | Attachment 3.1-A page 5.12b | |
| • • | | |
| | | |
| | | |
| | | |
| 10. SUBJECT OF AMENDMENT: | | |
| The primary purpose for this amendment is to obtain approval of an upda | | r to facilitate obtaining |
| brand and generic supplemental rebates in addition to the federal rebate p | provided for in Title XIX. | |
| 11. GOVERNOR'S REVIEW (Check One): | | |
| GOVERNOR'S OFFICE REPORTED NO COMMENT | OTHER, AS SPECIFIED: | |
| COMMENTS OF GOVERNOR'S OFFICE ENCLOSED | Governor's designee on file | |
| NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL | • | |
| | | |
| 12. SIGNATURE OF STATE AGENCY OFFICIAL: | 16. RETURN TO: | |
| //s// | Stephanie McGee Azar | |
| 12 TVDED NAME, Combania McCon Annu | Acting Commissioner | |
| 13. TYPED NAME: Stephanie McGee Azar | Alabama Medicaid Agency | |
| 14. TITLE: Acting Commissioner | 501 Dexter Avenue | |
| 14. TITLE: Acting Commissioner | Post Office Box 5624 | |
| 15. DATE SUBMITTED: 05-03-14 | Montgomery, Alabama 36103-5624 | |
| 13. DATE SUBMITTED, 03-05-14 | | |
| FOR REGIONAL O | FFICE USE ONLY | |
| 17. DATE RECEIVED: 05/03/13 | 18. DATE APPROVED: 07/25/13 | |
| | | |
| PLAN APPROVED – O | NE COPY ATTACHED | |
| 19. EFFECTIVE DATE OF APPROVED MATERIAL: 07/01/13 | 20. SIGNATURE OF REGIONAL | OFFICIAL: |
| | //s// | |
| 21. TYPED NAME: | | |
| | 22. TITLE: Associate Regional Ad | ministrator |
| Jackie Glaze | 22. TITLE: Associate Regional Ad Division of Medicaid & Children F | |
| Jackie Glaze | | |
| Jackie Glaze 23. REMARKS: | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

AL-13-011 Attachment 3.1-A Page 5.12b

- 12. Prescribed drugs, dentures, and prosthetic devices; and eyeglasses prescribed by a physician skilled in diseases of the eye or by an optometrist.
 - a. Prescribed Drugs Continued
 - (7) Auditing by Manufacturer

The state permits manufacturers to audit utilization data as stated in (6) above. Adjustments to rebates are made to the extent that information indicates that utilization was greater or less than previously specified.

(8) Prior Approval

The state provides for response by telephone or other communication devices, e.g., fax, within 24 hours of a request for prior approval and provides for the dispensing of at least a 72-hour supply of a covered outpatient prescription drug in an emergency situation.

(9) Supplemental Rebate Agreements

The state is in compliance with section 1927 of the Social Security Act. The state will cover drugs of federal rebate participating manufacturers. The state is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers can audit utilization data. The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification.

The state may negotiate brand and/or generic supplemental rebates in addition to the federal rebates provided for in Title XIX. Supplemental drug rebate agreements between the state and a pharmaceutical manufacturer will be separate from the federal rebates.

A supplemental drug rebate agreement between the state and a drug manufacturer for drugs provided to the Alabama Medicaid population, originally submitted to CMS on August 8, 2003, and an updated version submitted on May 3, 2013, entitled, "State of Alabama Supplemental Drug Rebate Contract," has been authorized by CMS.

Supplemental rebates received by the state in excess of those required under the national drug rebate agreement will be shared with the federal government on the same percentage basis as applied under the national rebate agreement.

All drugs covered by the program, irrespective of a prior authorization agreement, will comply with the provisions of the national drug rebate agreement.

(10) Preferred Drug List

Pursuant to 42 U.S.C. section 1396r-8 the state is establishing a preferred drug list with prior authorization for drugs not included on the preferred drug list. Prior authorization will be provided with a 24-hour turn-around from receipt of request and a 72-hour supply of drugs in emergency situations as in accordance with provisions of section 1927(d)(5) of the Social Security Act.

Prior authorization will be established for certain drug classes or particular drugs in accordance with federal law.

All drugs covered by the program irrespective of a prior authorization requirement will comply with the provisions of the national drug rebate agreement.

The state will utilize the Drug Utilization Review board to assure that in addition to pricing consideration, preferred drugs are clinically appropriate.

TN No. AL-13-011 Supersedes TN No. AL-03-06

Approval Date: 07-25-13

Effective Date: 07/01/13